A
Atrogi
Clinical-stage biotech company developing first-in-class, insulin-independent treatments for type 2 diabetes and related metabolic disorders
About Atrogi
Atrogi is a Swedish research company focused on developing a groundbreaking oral treatment for type 2 diabetes (T2D). The company operates in the pharmaceutical and biotechnology market, targeting patients suffering from T2D. Atrogi's core product is a potential first-in-class drug that offers a novel mechanism for managing glucose homeostasis, which has shown promising results in preclinical animal models. The business model revolves around advancing this drug through clinical trials and eventually partnering with or licensing to major pharmaceutical companies, thereby generating revenue through milestone payments, royalties, and licensing fees. The company is currently preparing for First in Human studies, with significant interest from big pharma, indicating strong market potential. Atrogi's team boasts over 20 years of experience in diabetes research, ensuring a focused and efficient drug development process.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Stockholm, Sweden
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 84.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2024 | $36M | $143M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Jun 2020 | $11M | $44M | Korea Investment Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Atrogi is 710 monthly website visits, down 29% over the last three months. Atrogi's team grew 21.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Korea Investment Partners
Other known investors1 additional known investor
Flerie Invest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atrogi on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atrogi’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.